171 results about "Oxyde nitrique" patented technology

Nanocomposite copper-ceria catalysts are provided, which comprise copper oxide nanoparticles, copper nanoparticles, or a mixture thereof combined with ceria nanoparticles. Methods for making such catalysts are also provided, which involve the steps of (i) combining ceria nanoparticles in an aqueous suspension with copper 2,4-pentanedionate to form a slurry; (ii) heating the slurry formed in step (i) under an inert gas atmosphere or an oxygen-argon atmosphere, at a temperature and for a time sufficient to cause decomposition of the copper 2,4-pentanedionate to form copper nanoparticles and / or copper oxide nanoparticles that are combined with the ceria nanoparticles; and (iii) optionally, subjecting the product formed in step (ii) to a heat treatment process under conditions effective to convert at least some of the copper nanoparticles to copper oxide nanoparticles. The nanocomposite copper-ceria catalysts are useful for low-temperature and near-ambient temperature catalysis, such as the oxidation of carbon monoxide, the reduction of nitric oxide and the conversion of hydrocarbons. The nanocomposite copper-ceria catalysts have a variety of potential applications, for example, in vehicle exhaust emission systems of automobiles and diesel engines, cold starting of automobile engine, fuel cells, lasers, hydrocarbon conversion reactors, air filters for the conversion of carbon monoxide and / or indoor volatile organic compounds, and smoking articles.

The present invention relates to heteroarylacrylamides of the formula I,in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

Cold storage solutions for the preservation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, and a glutathione-forming agent.

Provided according to embodiments of the invention are novel tertiary alkyl thiol compounds and novel tertiary alkyl nitrosothiol compounds. Further provided according to embodiments of the invention are methods of forming a nitric oxide (NO)-releasing xerogel coating that include (a) co-condensing a sol precursor solution comprising at least one backbone alkoxysilane and at least one tertiary thiol alkoxysilane in a solvent to form a sol; (b) coating a substrate with the sol; (c) optionally, drying the sol to form the xerogel coating; and (d) contacting the xerogel coating with a nitrosating agent. Methods of using xerogel coatings are also included.

The invention describes novel nitrosated and / or nitrosylated nebivolol, novel nitrosated and / or nitrosylated metabolites of nebivolol and novel compositions comprising at least one nitrosated and / or nitrosylated nebivolol and / or at least one nitrosated and / or nitrosylated metabolite of nebivolol, and, optionally, at least one nitric oxide donor and / or at least one antioxidant or a pharmaceutically acceptable salt thereof, and / or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and / or at least one nitrosated compound used to treat cardiovascular diseases. The invention also provides novel compositions comprising nebivolol and / or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and / or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and / or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and / or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and / or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and / or preventing Raynaud's syndrome; and for treating and / or preventing cardiovascular diseases or disorders.

A cosmetic treatment device includes a nitric oxide (NO) eluting polymer, a carrier, and a proton donor enclosed in a container that keeps the proton donor separate from the nitric oxide eluting polymer until the device is used. When the container is opened, proton donor contacts the polymer, causing the elution of nitric oxide from the polymer.

The invention relates to a quantum dot / polymer composite nitric oxide fluorescent probe and a preparation method thereof. The fluorescent probe is a powdered solid and is prepared from a quantum dot and methyl methacrylate (MMA) by an in-situ composite method, wherein the quantum dot and MMA polymer are combined though a covalent bond. The preparation method comprises the following steps of: 1) dispersing and dissolving water-soluble cadmium salt in a mixed solution of the MMA and a coupling agent, performing prepolymerization reaction at the temperature of between 70 and 90 DEG C under the action of an initiator under the protection of N2, and stopping reacting when the viscosity of a system is approximate to that of glycerol; 2) adding an aqueous solution of a sulfur source, a selenium source or a tellurium source into the prepolymer system in the step 1) dropwise with violent stirring under the protection of the N2 until the system is quickly discolored, wherein the molar ratio of the sulfur source, the selenium source or the tellurium source to the cadmium salt is 1.1:1-1.4:1; and 3) polymerizing at the temperature of between 50 and 70 DEG C for 10 to 24 hours. The fluorescent probe has the double advantages of the quantum dot and the polymer, is high in stability and is suitable for detecting nitric oxide in a sample to be detected.

A compound of the formula:wherein R1 is an aliphatic hydrocarbon group optionally having substituent(s), an aromatic hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a group of the formula: OR1a wherein R1a is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), or a group of the formula:wherein R1b and R1c are the same or different and each is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), X is a methylene group, a nitrogen atom, a sulfur atom or an oxygen atom, Y is an optionally substituted methylene group or an optionally substituted nitrogen atom, ring A is a 5 to 8-membered ring optionally substituted further by 1 to 4 substituent(s) selected from (1) an aliphatic hydrocarbon group optionally having substituent(s), (2) an aromatic hydrocarbon group optionally having substituent(s), (3) a group of the formula: OR2 wherein R2 is a hydrogen atom, or an aliphatic hydrocarbon group optionally having substituent(s) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituent(s), a group of the formula:is a group of the formula:or the formula:m is an integer of 0 to 2, n is an integer of 1 to 3, and the sum of m and n is not more than 4, provided that when X is a methylene group, Y is an optionally substituted methylene group, and a salt thereof have an inhibitory activity on nitric oxide (NO) production and cytokine production, and are useful as an agent for the prophylaxis and / or treatment of diseases, such as cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, septic shock and the like.

The invention relates to the field of coal ethylene glycol chemical engineering and particularly relates to a system and method for recovering methyl nitrite through a coal ethylene glycol carbonyl synthesis system. According to the method, the main target of effectively recovering a methyl nitrite gas is achieved in the coal ethylene glycol carbonyl synthesis system through the methods of combining air stripping, flash evaporation and nitric acid reduction. The recovery system mainly comprises a front air stripping system for methyl nitrite, a nitric acid reduction system and a rear air stripping system, wherein the front air stripping system is provided with a liquid-phase preheater, a front air stripping tower and a liquid-phase discharge centrifugal pump; the nitric acid reduction system is provided with a liquid-phase feeding preheater and a nitric acid reduction tower; and the rear air stripping system is provided with the flash evaporation tank, the liquid-phase feeding centrifugal pump and the rear air stripping tower. Stable content of nitric oxide and the methyl nitrite in a gas-phase component of the synthesis system is ensured through the method of combining a physical process and chemical reaction, the losses of the nitric oxide and the methyl nitrite are avoided to a great extent, the waste is changed into treasure, and resource waste and water source pollution are reduced.

The invention discloses the preparing method and application of cambogic acid derivation. The cambogic acid derivation is made by nitric oxide donator and cambogic acid. The cambogic acid derivation has the antineoplastic action.

The present invention describes novel nitrosated and / or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and / or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

The invention relates to nitric oxide donor OA or UA derivatives formed by coupling various types of NO donors and oleanolic acid (OA) or uraolic acid (UA) which is a medicament for treating liver diseases through ester bonds or amido bonds of link groups respectively. Bioactivity researches show that some compounds have the effects of killing liver tumor cells and have an application prospect in liver cancer treatment.

A medical device is provided which is adapted for implantation or insertion into the vasculature. The medical device has (a) a medical device substrate; (b) a lower polymeric layer, provided over the substrate made of a nitric oxide donor and a polymer; and (c) an upper polymeric layer, provided over the lower polymer layer, made of a polymer and an anti-restenotic agent.

The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and / or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.

The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and / or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and / or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

The invention relates to the field of pharmaceutical chemistry and particularly provides a polydatin (PD) derivative containing a NO (nitric oxide) donor. A PD (3,4',5-trihydroxystilbene-3-beta-D-glucoside)4' hydroxyl group and a corresponding nitrate ester are subjected to chemical reaction so as to generate the NO donor type PD derivative which is in ester bond connection. After being absorbed into a lung tissue, the compound is subjected to biological transformation and ester bond breakage so that a bulk pharmaceutical chemical PD and the NO donor are dissociated, the NO donor can release NO slowly, and NO and PD can play roles of reducing pulmonary hypertension, relieving right ventricular hypertrophy, improving the pulmonary vascular endothelium function and resisting lipid peroxide cooperatively. The NO donor type PD derivative has an application in the aspect of preparing medicaments for preventing or treating pulmonary hypertension and high altitude pulmonary edema diseases caused by oxygen deficiency.

Disclosed herein are cyclodextrin molecules covalently modified to store and release nitric oxide, as well as methods of making and uses thereof. The covalently modified cyclodextrin molecules may be tailored, in several embodiments, to release nitric oxide in a controlled manner and are useful for reduction and / or eradication of bacteria and for the treatment of disease.